NanoViricides Inc
NNVC
Get informed when a big investor buys or sells
+ FollowMarket Cap$36.07M
Close$
$0.10
92.5% downside
Current Fair Value
92.5% downsideOvervalued by 92.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $36.07 Million |
|---|---|
| Enterprise Value | $-3,213,219,933,136.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.63 |
| Beta | 1.67 |
| Outstanding Shares | 21,609,000 |
Return
| Return on Equity | -21.73% |
|---|---|
| Return on Assets | -19.47% |
| Return on Invested Capital | -22.18% |
Valuation & Multiples
| P/E Ratio | -3.29 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 1.58 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 21, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
September 2, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 35,900▼ 6.27% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 8.79%▼ 6.86% |
|---|---|
| Total Invested | $1.73M▼ 50.64% |
| Investors Holding | 49▲ 4.00% |
ESG Score
No data
About NanoViricides Inc
12 employeesNanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus parti...